Effectiveness of Smoking Cessation Program in a Community Health System
NCT ID: NCT05107687
Last Updated: 2024-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
76 participants
OBSERVATIONAL
2021-05-10
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Developing a Scalable Tobacco Cessation Program for Cancer Survivors and Caregivers
NCT06851936
Effectiveness of Intensive Smoking Cessation Interventions in Patients With Cancer
NCT04198688
Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
NCT03291587
Motivating a Spectrum of Cancer Patients to Quit Smoking
NCT04914000
Designing an Implementation Strategy for Lung Screening and Smoking Cessation Treatment in Community Health Centers
NCT05447897
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary:
To determine the effectiveness of an intensive structured smoking cessation program (education and support) provided by a tobacco cessation trained specialist versus unassisted smoking cessation quitting methods (no support, patients have opted to stop on their own) in cancer patients seen in a community health care system
Secondary:
* Self-reported 7-day point-prevalence smoking abstinence at 6-month follow-up in patients participating in a structured smoking cessation program versus those patients that have quit smoking with professional support
* Self-reported 7-day point-prevalence smoking abstinence at 12-month follow-up in patients participating in a structured smoking cessation program versus those patients that have quit smoking without professional support, participants choosing to stop smoking on their own.
* Examine the impact of implementing a system level smoking cessation program into the ongoing management of our cancer patients who smoke.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Assisted Smoking Cessation
Subject participates in a structured smoking cessation program hosted at Virtua Health which may be either smoking cessation group sessions or individual sessions and/or both. All participants will be provided with a list of smoking cessation resources.
Description of Group Smoking Education and Support: These sessions are led by a Tobacco Treatment Specialist and include 2-3 sessions in-person or virtually and cover the following topics: Biological changes caused by nicotine, addiction, tips to quit smoking, health benefits to quitting smoking, types of nicotine replacement therapy, e-cigarettes and devices, aromatherapy, meditation and various resources. In addition, access to nicotine replacement therapies is optional.
Smoking cessation
Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.
Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.
The subject selects their preferred intervention.
Unassisted Smoking Cessation
The subject receives no professional support but is provided with a list of smoking cessation resources, in this cohort the subject engages in smoking cessation with no assistance from a provider.
Smoking cessation
Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.
Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.
The subject selects their preferred intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Smoking cessation
Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.
Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.
The subject selects their preferred intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over 18 years of age
* Able to read and understand English
* Able to sign the informed consent form
* A current cigarette smoker defined as smoking within 30 days
* Diagnosed with cancer and wants to quit smoking
Exclusion Criteria
* ECOG Performance Status 3-4
* Survival prognosis less than 12 months
* Currently participating in a smoking cessation program that is not provided by Virtua
* Individuals who do not want to quit smoking
* Pregnant Women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Virtua Health, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Theresa Carducci, MSN, RN, CCRP
Role: PRINCIPAL_INVESTIGATOR
Virtua Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virtua Health
Voorhees Township, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-2021-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.